23.4.2018 |
EN |
Official Journal of the European Union |
C 142/49 |
Judgment of the General Court of 9 March 2018 — Recordati Orphan Drugs v EUIPO — Laboratorios Normon (NORMOSANG)
(Case T-103/17) (1)
((EU trade mark - Opposition proceedings - Application for EU word mark NORMOSANG - Earlier national word mark NORMON - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) - Rule 19(2)(a)(ii) and Rule 20(1) of Regulation (EC) No 2868/95 (now Article 7(2)(a)(ii) and Article 8(1) and (7) of Delegated Regulation (EU) 2017/1430)))
(2018/C 142/65)
Language of the case: English
Parties
Applicant: Recordati Orphan Drugs (Puteaux, France) (represented by: J. Quirin, lawyer)
Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Laboratorios Normon, SA (Tres Cantos, Spain) (represented by: I. Gonzalez-Mogena Gonzalez, lawyer)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 22 November 2016 (Case R 831/2016-5), relating to opposition proceedings between Laboratorios Normon and Recordati Orphan Drugs.
Operative part of the judgment
The Court:
1. |
Dismisses the action; |
2. |
Orders Recordati Orphan Drugs to pay the costs. |